Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 3/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24540960 | 0.86 | CHRNB2 (0.39) | CSF1RCHRNA7 | |
| SCHEMBL24540736 | 0.82 | SMN1; SMN2 (0.34) | MAPT | |
| SCHEMBL24540735 | 0.82 | SMN1; SMN2 (0.34) | MAPT | |
| SCHEMBL24540747 | 0.82 | SMN1; SMN2 (0.34) | MAPT | |
| SCHEMBL24540730 | 0.78 | GPR174 (0.38) | MAPTGPR174CSF1R | |
| SCHEMBL24541182 | 0.77 | CHRNB2 (0.43) | CHRNA7 | |
| SCHEMBL24540924 | 0.73 | TRPV4 (0.38) | DRD2DRD3 | |
| SCHEMBL24547910 | 0.73 | TRPV4 (0.38) | DRD2DRD3 | |
| SCHEMBL24540925 | 0.73 | TRPV4 (0.38) | DRD2DRD3 | |
| SCHEMBL31043203 | 0.73 | TRPV4 (0.38) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732837-A2 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11845760-B2 | PRMT5 inhibitors | AMGEN INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | MAPT 3592/4885GPR174 4267/4885CSF1R 579/4885 |
| US-11845760-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | MAPT 3444/4885GPR174 4384/4885CSF1R 560/4885 |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | MAPT 3592/4885GPR174 4267/4885CSF1R 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.